Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 90.8% in October

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 29,000 shares, a growth of 90.8% from the October 15th total of 15,200 shares. Currently, 0.6% of the shares of the company are sold short. Based on an average daily trading volume, of 21,900 shares, the short-interest ratio is presently 1.3 days.

Analyst Upgrades and Downgrades

APRE has been the subject of a number of research analyst reports. Wedbush restated an “outperform” rating and set a $11.00 price objective on shares of Aprea Therapeutics in a research report on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Aprea Therapeutics in a research note on Thursday, October 24th.

Insider Buying and Selling

In other news, Director Bernd R. Seizinger acquired 10,000 shares of the business’s stock in a transaction on Friday, October 11th. The stock was bought at an average price of $2.68 per share, with a total value of $26,800.00. Following the completion of the acquisition, the director now owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Aprea Therapeutics news, Director Marc Duey sold 6,462 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $4.58, for a total value of $29,595.96. Following the sale, the director now directly owns 233,651 shares of the company’s stock, valued at approximately $1,070,121.58. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bernd R. Seizinger bought 10,000 shares of Aprea Therapeutics stock in a transaction dated Friday, October 11th. The shares were acquired at an average cost of $2.68 per share, with a total value of $26,800.00. Following the completion of the purchase, the director now owns 44,730 shares in the company, valued at approximately $119,876.40. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 42,290 shares of company stock valued at $165,096. Corporate insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aprea Therapeutics stock. Stonepine Capital Management LLC purchased a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics comprises about 0.5% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 21st biggest position. Stonepine Capital Management LLC owned about 2.53% of Aprea Therapeutics at the end of the most recent reporting period. 34.19% of the stock is owned by institutional investors.

Aprea Therapeutics Trading Down 3.8 %

Shares of APRE opened at $3.30 on Thursday. The stock has a 50 day moving average price of $3.35 and a 200 day moving average price of $3.93. Aprea Therapeutics has a one year low of $2.15 and a one year high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last issued its earnings results on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.11. The business had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.45 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. Equities analysts anticipate that Aprea Therapeutics will post -2.56 earnings per share for the current fiscal year.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.